Skip to content

Registration of the Study of Reyanning Mixture

A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial of the Efficacy and Safety of Treating Acute Tonsillitis With Reyanning Mixture Alone/in Combination With Antibiotics.

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03704506
Enrollment
144
Registered
2018-10-12
Start date
2018-10-22
Completion date
2019-12-31
Last updated
2018-10-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Tonsillitis

Keywords

Reyanning mixture, efficacy, safety, randomized, double-blind, placebo-controlled, multicenter, antibiotics

Brief summary

The purpose of this study is to evaluate the efficacy and safety of treating with acute tonsillitis using Reyanning mixture alone/in combination with antibiotics, and its function of reducing the use of antibiotics.

Detailed description

In order to evaluate the efficacy,safety and the function of reducing the use of antibiotics of Reyanning mixture (a mixture of Chinese herbal medicine) in treating with acute tonsillitis, a randomized, double-blind, placebo-controlled, multicenter clinical trials will be established. According to the relevant regulations of the China Food and Drug Administration(CFDA), 144 cases need to be registered at least. The aim population is who suffering of acute tonsillitis from October 2018 to December 2019.These cases will be randomly divided into treatment group 1(Reyanning mixture +amoxil capsule simulator),treatment group 2(Reyanning mixture +amoxil capsule) and control group(Reyanning mixture simulator +amoxil capsule).Each group will be treated for 7 days and followed up for 3 times . The main indicators include the recovery time/rate and antibiotic duration/dosage. And the vanish rate of single symptom/physical sign, the ratio of white blood cell count(WBC) recovery, the time of fever will be observed as well.

Interventions

DRUGReyanning mixture

Reyanning mixture , 20ml by mouth , 3 times per day for 7 days

DRUGamoxil capsule

amoxil capsule , 0.5g by mouth , 3 times per day for 7 days

DRUGReyanning mixture simulator

Reyanning mixture simulator , 20ml by mouth , 3 times per day for 7 days

DRUGamoxil capsule simulator

amoxil capsule simulator , 0.5g by mouth , 3 times per day for 7 days

Sponsors

The First Affiliated Hospital of Henan University of Traditional Chinese Medicine
CollaboratorOTHER
Beijing Chao Yang Hospital
CollaboratorOTHER
Wangjing Hospital, China Academy of Chinese Medical Sciences
CollaboratorOTHER
Beijing First Hospital of integrated Chinese and Western Medicine
CollaboratorOTHER
China Academy of Chinese Medical Sciences
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

1. Meet the diagnostic criteria of acute tonsillitis; 2. Meet the traditional Chinese medicine symptom diagnostic criteria of external wind-heat type and excessive heat in the lung and stomach type; 3. 18 years≤age≤65 years; 4. course of disease within 72 hours; 5. sign informed consent.

Exclusion criteria

1. common cold,influenza, acute laryngopharyngitis, pharyngeal diphtheria, wensang's isthmitis. 2. complicated with acute tracheobronchitis,pneumonia,rheumatic fever, acute glomerulonephritis or rheumatic heart disease. 3. complicated with severe angiocardiopathy, cerebrovascular disease, hemopoietic system disease or psychopath. 4. liver or kidney function is abnormal(ALT\>1.5 times upper limit of normal; Cr\>upper limit of normal); diabetic. 5. WBC\<10×109/L and neutrophilic granulocyte percentage\<75%;or WBC ≥20×109/L; 6. gestational, lactating women or who planning to get pregnant within half a year. 7. already accept similar traditional Chinese medicine or antibiotic within 48 hours before registered. 8. joining other clinical trials or allergic to any drug in this trials.

Design outcomes

Primary

MeasureTime frameDescription
antibiotic durationafter 7 days of medicationThe duration of antibiotic will be observed.
recovery rateafter 3 days of medicationThe recovery rate will be observed. Recovery means that the main signs and symptoms score is zero, and body temperature is below 37.3 ℃ maintaining for at least 24 hours.
recovery timeafter 3 days of medicationThe recovery time will be observed. Recovery means that the main signs and symptoms score is zero, and body temperature is below 37.3 ℃ maintaining for at least 24 hours.
antibiotic dosageafter 7 days of medicationThe dosage of antibiotic will be observed.

Secondary

MeasureTime frameDescription
the time of fever relievingafter 7 days of medicationThe time of fever relieving means that the duration from the first medication to the body temperature drops below 37.3℃ maintaining for at least 24 hours.
the vanish rate of single symptom/physical signafter 3 days of medicationThe single symptom/physical sign include tonsil redness, pharyngeal pain, and fever.
the ratio of WBC recoveryafter 7 days of medicationThe ratio of WBC recovery refers to the percentage of white blood cell count which return to normal range after 7 days of medication.

Other

MeasureTime frameDescription
To observe if Reyanning mixture causes liver function damage.after 7 days of medicationto assess the liver function indicators
To observer if Reyanning mixture causes renal damageafter 7 days of medicationto assess the urinalysis indicators
To observer if Reyanning mixture impacts renal functionafter 7 days of medicationto assess the renal function indicators ,including serum creatinine(Cr) and glomerular filtration rate( eGFR)

Contacts

Primary ContactYanming Xie, BA
ktzu2018@163.com86-13911112416
Backup ContactLianxin Wang, Doctor
wlxing@126.com86-13521781839

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026